Abstr#0846 ⁦@RheumNow⁩ #acr19 #acrbest Eval of MACE and VTE of UPA based on phs 3 trials: 1. NO ⬆️risk MACE/VTE over 2 yrs compared to MTX, ADA 2. NO correl. w/lipid levels, dose of drug with MACE/VTE and UPA. * despite the safety seen, UPA’s label still include VTE risk https://t.co/unOBvoW8Ub